Interesting article on Royaty deals with biotech and pharma, the trend in royalties in biotech is growing 

"Similarly, Pablo Legorreta of Royalty Pharma has said interest in royalty deals rose more than 50% between 2019 and 2021. In May 2022, this prompted them to almost double their capital deployment target to $10-12 billion over the next five years."

https://eradigm.com/royalties-in-pharma-a-closer-look-at-the-company-which-owns-a-stake-in-a-quarter-of-all-blockbuster-drugs-and-the-growing-significance-of-the-model-they-created/